Eagle Pharmaceuticals, Inc. (EGRX): Price and Financial Metrics


Eagle Pharmaceuticals, Inc. (EGRX)

Today's Latest Price: $48.46 USD

0.44 (-0.90%)

Updated Jul 2 4:00pm

Add EGRX to Watchlist
Sign Up

Overall POWR Rating


POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank


Industry Rank:

Ranked of 214 in Medical - Pharmaceuticals

See all "A" rated Strong Buy stocks

EGRX Stock Summary

  • With a price/earnings ratio of 265.94, Eagle Pharmaceuticals Inc P/E ratio is greater than that of about 98.44% of stocks in our set with positive earnings.
  • With a year-over-year growth in debt of 249.49%, Eagle Pharmaceuticals Inc's debt growth rate surpasses 93.69% of about US stocks.
  • As for revenue growth, note that EGRX's revenue has grown -11.25% over the past 12 months; that beats the revenue growth of only 16.95% of US companies in our set.
  • If you're looking for stocks that are quantitatively similar to Eagle Pharmaceuticals Inc, a group of peers worth examining would be SMTC, GORO, BLKB, CYBR, and SSTI.
  • Visit EGRX's SEC page to see the company's official filings. To visit the company's web site, go to www.eagleus.com.
EGRX Daily Price Range
EGRX 52-Week Price Range

EGRX Stock Price Chart Technical Analysis Charts


EGRX Price/Volume Stats

Current price $48.46 52-week high $64.94
Prev. close $48.90 52-week low $33.80
Day low $48.02 Volume 285,361
Day high $49.94 Avg. volume 175,709
50-day MA $50.41 Dividend yield N/A
200-day MA $53.39 Market Cap 663.18M

Eagle Pharmaceuticals, Inc. (EGRX) Company Bio


Eagle Pharmaceuticals focuses on developing and commercializing injectable products primarily in the critical care and oncology areas in the United States. The company was founded in 2007 and is based in Woodcliff Lake, New Jersey.

EGRX Price Forecast Based on DCF Valuation

Current PriceDCF Fair Value Target:Forecasted Gain:
$48.46$109.59134%

Below please find a table outlining a discounted cash flow forecast for EGRX, in which we model out valuation assuming a variety of terminal growth rates. To summarize, we found that Eagle Pharmaceuticals Inc ranked in the 66th percentile in terms of potential gain offered. Specifically, our DCF analysis implies the stock is trading below its fair value by an estimated 135.5%. The most interesting components of our discounted cash flow analysis for Eagle Pharmaceuticals Inc ended up being:

  • In the past 4.99 years, Eagle Pharmaceuticals Inc has a compound free cash flow growth rate of 0.39%; that's better than 77.61% of cash flow producing equities in the Healthcare sector, where it is classified.
  • Eagle Pharmaceuticals Inc's effective tax rate, as measured by taxes paid relative to net income, is at 31 -- greater than 90.94% of US stocks with positive free cash flow.


Terminal Growth Rate in Free Cash FlowReturn Relative to Current Share Price
0%130%
1%132%
2%134%
3%137%
4%139%
5%141%

Want more companies with a valuation profile/forecast similar to that of Eagle Pharmaceuticals Inc? See MCK, HUM, FTLF, ENDP, and ABBV.


EGRX Latest News Stream


Event/TimeNews Detail
Loading, please wait...

EGRX Latest Social Stream


Loading social stream, please wait...

View Full EGRX Social Stream

Latest EGRX News From Around the Web

Below are the latest news stories about Eagle Pharmaceuticals Inc that investors may wish to consider to help them evaluate EGRX as an investment opportunity.

Hedge Funds Are Buying Eagle Pharmaceuticals Inc (EGRX)

The financial regulations require hedge funds and wealthy investors that exceeded the $100 million equity holdings threshold to file a report that shows their positions at the end of every quarter. Even though it isn't the intention, these filings to a certain extent level the playing field for ordinary investors. The latest round of 13F […]

Yahoo | June 28, 2020

Edited Transcript of EGRX earnings conference call or presentation 11-May-20 12:30pm GMT

Q1 2020 Eagle Pharmaceuticals Inc Earnings Call

Yahoo | June 10, 2020

Eagle Pharmaceuticals to Present at June Investor Conferences

WOODCLIFF LAKE, N.J.--(BUSINESS WIRE)--Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) (“Eagle” or the “Company”) today announced that Scott Tarriff, Chief Executive Officer, and Pete Meyers, Chief Financial Officer, will present at two upcoming investor conferences as follows: Conference: Jefferies Virtual Healthcare Conference Date: Thursday, June 4, 2020 Time: 1:00 p.m. ET Webcast: http://wsw.com/webcast/jeff126/egrx/ Conference: William Blair Virtual 40th Annual Growth Stock Conference Date: T

Business Wire | May 26, 2020

Eagle Pharmaceuticals Announces Change to Virtual Format for 2020 Annual Meeting of Stockholders

WOODCLIFF LAKE, N.J.--(BUSINESS WIRE)--Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) (“Eagle”) announced today that, due to public health and safety concerns related to the ongoing COVID-19 global pandemic, recommendations and orders from federal, state and local authorities, and to support the health and well-being of its stockholders, employees and others, Eagle is changing its 2020 Annual Meeting of Stockholders (the “Annual Meeting”) to a virtual-only format that will be held via live audio we

Business Wire | May 22, 2020

Eagle Pharmaceuticals to Present at the 2020 RBC Capital Markets Global Healthcare Virtual Conference

WOODCLIFF LAKE, N.J.--(BUSINESS WIRE)--Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) (“Eagle” or the “Company”) today announced that Scott Tarriff, Chief Executive Officer, and Pete Meyers, Chief Financial Officer, will host a fireside chat at the 2020 RBC Capital Markets Global Healthcare Virtual Conference as follows: Date: Tuesday, May 19, 2020 Time: 3:05 p.m. Eastern Time Webcast: https://www.veracast.com/webcasts/rbc/healthcare2020/01112239705.cfm The presentation will be webcast live a

Business Wire | May 12, 2020

Read More 'EGRX' Stories Here

EGRX Price Returns

1-mo -2.06%
3-mo 2.39%
6-mo -15.55%
1-year -14.11%
3-year -40.65%
5-year -41.55%
YTD -19.34%
2019 49.12%
2018 -24.58%
2017 -32.67%
2016 -10.52%
2015 472.06%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!



Page generated in 0.8479 seconds.